PET developer Positron has received approval from the U.S. Nuclear Regulatory Commission (NRC) for the company's manufacturing and distribution license amendment for a radiopharmaceutical manufacturing facility in Crown Point, IN.
Positron received its pharmacy license from the Indiana Board of Pharmacy in December 2011, which served as a precursor to the NRC amendment and approval, allowing Positron to manufacture and distribute radiochemicals and radiopharmaceuticals throughout the U.S.
The company said it is currently producing indium-111 oxyquinoline for customer evaluation and commercial sale, with plans to process additional radioisotopes for medical use.
